Search

Displaying results 7181 - 7190 of 10000 in total
  1. Drug

    IPH 2101

    go.drugbank.com/drugs/DB06049
    Investigational

    IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

  2. Drug

    XTL-6865

    go.drugbank.com/drugs/DB06058
    Investigational

    It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.

  3. Drug

    AZD-8330

    go.drugbank.com/drugs/DB06061
    Investigational

    AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival.

  4. Drug

    Citatuzumab Bogatox

    go.drugbank.com/drugs/DB06072
    Investigational

    VB6-845 is a humanized antibody fragment targeting EpCAM fused with the deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer.

  5. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels

    Categories: Receptor Protein-Tyrosine Kinases, antagonists & inhibitors
  6. Drug

    Friulimicin B

    go.drugbank.com/drugs/DB06087
    Investigational

    Friulimicin B is a naturally occurring antibiotic produced by a micro-organism, *Actinoplanes friuliensis*. … It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community.

  7. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  8. Drug

    3,4-Methylenedioxy-N-isopropylamphetamine

    go.drugbank.com/drugs/DB06112
    Experimental

    MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").

  9. Drug

    Tesofensine

    go.drugbank.com/drugs/DB06156
    Investigational

  10. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. … The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]